Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NIMGenetics

Explore full profile

An analytical Diagnosis Center with a Genetics unit authorized by the Department of Health of the Community of Madrid

Madrid, SpainFounded 2008Biotech & Life Sciences
Valuation $25–50M Last recorded · 2021
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NIMGenetics and the history behind them.

About NIMGenetics

NIMGenetics operates as a specialized analytical diagnostic center with a dedicated genetics unit, officially authorized by the Health Council of the Community of Madrid since 2009. The company was founded by Dr. Enrique Samper and Javier Pérez. Dr. Samper, who holds a PhD in Biological Sciences and has an extensive background in researching telomeres, cellular aging, and cancer at prestigious institutions like the Cold Spring Harbor Laboratory and the Spanish National Cancer Research Centre (CNIO), serves as the scientific lead. Javier Pérez, a partner, likely complements this with business or operational expertise.

Read full description

The firm focuses on the development and application of high-resolution genomic systems to provide precise clinical diagnostics. Its core business involves offering advanced genomic tools to medical professionals, aiming to enhance healthcare in areas like prevention, prognostic characterization, and diagnostic reliability. A key product is KaryoNIM®, a genomic tool that helps identify copy number variations in DNA that have phenotypic repercussions. Since 2008, the company has received support from the Centre for the Development of Industrial Technology (CDTI), which has bolstered its innovation capacity.

NIMGenetics serves a client base that includes over 50 diagnostic centers, clinics, and hospitals. Beyond its clinical diagnostic services, the company also caters to researchers and research services. For this segment, it provides a wide array of genomic tools coupled with personalized support that spans from experimental design and platform selection to comprehensive bioinformatic analysis. This dual focus on both clinical and research applications positions the company as a key player in the Spanish genetics and genomics market.

Source: Dealroom company data

At a glance

Founded
2008
Headquarters
Madrid, Spain
Sector
Biotech & Life Sciences

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Apposite Capital

Series B and later1 investor entered at this stage

  • ENISA
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇪🇸 Spain89.7%
🇲🇽 Mexico2.6%
🇵🇹 Portugal2.6%
🇧🇷 Brazil2.6%
🇪🇨 Ecuador2.6%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NIMGenetics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NIMGenetics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.